U.S. and Global Sickle Cell Market

WASHINGTON, November 22, 2021 (GLOBE NEWSWIRE) – According to a new report from Vantage Market Research, the world ssickle cell market Cut is expected to reach $ 7.9 billion by 2028, with a CAGR of 7.81% during the forecast period. Increasing patient base, advanced therapies and increasing R&D activities are some of the factors that are driving the growth of the market, says Vantage Market Research, in a report titled “Sickle Cell Disease Market By Treatment Type (Blood Transfusion, Drug Therapy, Bone Marrow Transplant), By End User (Hospitals, Diagnostic Centers, Others): Global Industry Perspective, Comprehensive Analysis and Forecast, 2020-2028.The market size was $ 1.4 billion in 2020.

The Sickle Cell Disease Market Report Highlights:

  • Market assessment
  • Premium previews
  • Competitive landscape
  • COVID impact analysis
  • Historical data, estimates and forecasts
  • Company Profiles
  • Global and regional dynamics

Market Snapshot:

Increased research and development activity to drive high market growth

Increased research and development activities, patient pool growth and a strong pipeline are expected to fuel the Sickle Cell Disease market growth over the projected period. For example, the United States Food and Drug Administration has approved Voxelotor for the treatment of sickle cell anemia. Likewise, Global Blood Therapeutics worked on development trials for 10 drugs including Anti-sicking, HbF inducer, Inclacumab, Voxelotor and GF1021601, etc. sickle cell market demand.

Get a sample PDF copy of this report to understand the structure of the full report: (including full table of contents, list of tables and figures, graph) @ https://www.vantagemarketresearch.com/industry-report/sickle-cell-disease-diagnosis-market-0209/request-sample

Rise in Sickle Cell Blood Transfusion Treatment Fuels Strong Market Demand

Rising prevalence of sickle cell disease and high demand for blood transfusion in the treatment of sickle cell disease are the factors driving the market growth. Blood transfusions help the normal supply of red blood cells to increase hemoglobin levels in the body. This in turn improves the oxygen supply and reduces the blockage of sickle cells in the blood vessels. This is the reason for the high demand for blood transfusion in the market. In addition, plasma transfusion is also useful for the treatment of sickle cell anemia. Thus, it is fueling the growth of sickle cell therapy by blood transfusion during the forecast period.

Regional analysis:

North America Dominates Sickle Cell Market

North America is expected to dominate sickle cell disease and be the largest contributor to the market. This is attributed due to potential pipeline candidates and improved access to SCD treatment. The main factor to stimulate the market growth in the region is the strong support from the government. According to the National Biotechnology Information Centers, the NHLBI (National Institute of Heart, Lungs and Blood) has launched collaborative research to accelerate the development of genetic therapies to cure SCD.

List of Major Sickle Cell Disease Market Players:

Sr. No. Companies The head office
1. Novartis AG Basel, Switzerland
2. Pfizer Inc. New York, United States
3. Global Blood Therapeutics Inc. South San Francisco, California, United States
4. Emmaüs Medical Inc. Torrance, California, United States
5. Eli Lilly & Company Indianapolis, Indiana, United States
6. Addmedica inc. Paris, France
7. Medunik USA. Inc. Rosemont, Pennsylvania
8. Bristol Myers Squibb Co. New York, United States
9. Baxter Inc. Deerfield, Illinois, United States
ten. Bluebird Biotechnology Massachusetts, United States
11. Glycomimetics Inc. Rockville, Maryland
12. F. Hoffmann-La Roche Basel, Switzerland
13. CRISPR Therapeutics Zug, Switzerland

Request for pre and post COVID-19 impact analysis on companies: https://www.vantagemarketresearch.com/insight/press-release/sickle-cell-disease-diagnosis-market-689085

Recent developments in the industry:

November 1, 2021: Novartis AG has announced new analyzes of the two-year positive phase III study JUNIPERA. This study demonstrates the response to treatment of Cosentyx® (secukinumab) in children and adolescents with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) – two categories of juvenile idiopathic arthritis (JIA) .

October 2, 2021: Novartis AG announced that the FDA has approved Scemblix® for the treatment of chronic myelogenous leukemia (CML) in two separate indications.

June 3, 2021: Global Blood Therapeutics Inc. announced that the MHRA in the UK has granted Voxelotor a Promising Innovative Medicine (PIM) designation for the potential treatment of hemolytic anemia in adult and adolescent patients 12 years and older with sickle cell anemia (SCD).

This report provides details about the prevalence, incidence, patient breakdown, average treatment price, market and technological trends, and new product developments of the Sickle Cell Disease market.

.Report attribute Details
Year of reference 2020
Historical years 2016 – 2019
Forecast years 2021 – 2028
Covered segments
  • Type of treatment
    • Blood transfusion
    • Pharmacotherapy
    • Bone marrow transplant
  • Final user
    • Hospitals
    • Diagnostic centers
    • Others
Quantitative Data – Units Revenue in millions USD / billion
Regions covered North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, and rest of the world
Covered countries United States, Canada, Mexico, United Kingdom, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC countries and South Africa, among others
Cover of the report Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, market share analysis of the business and impact assessment of COVID-19.

Do you have a specific question or requirement? Ask our industry expert @ https://www.vantagemarketresearch.com/industry-report/sickle-cell-disease-diagnosis-market-0209/inquiry-before-buying

Contents –

  1. Chapter n ° 1: Introduction
    1. Scope of the report
    2. Objectives of the study
    3. USP Offers and Keys
    4. Target audience
    5. Vantage Tips / Walkthrough Market Research Report
  2. Chapter 2: Premium Previews
    1. Market Snapshot
    2. Better investment pockets
      1. Market attractiveness analysis, by type
      2. Market attractiveness analysis, by end user
      3. Market attractiveness analysis, by Middle East and Africa
    3. Views of key informants
  3. Chapter 3: Key Market Dynamics
    1. introduction
    2. Market factors
    3. Market constraints
    4. Market opportunities
    5. Porter’s Five Forces Analysis
    6. PEST analysis
    7. Regulatory landscape
    8. Technological landscape
    9. Regional market trends

Table of contents continued …

Related Research Reports Studies:

The Global Pain Management Therapy Market was valued at $ 68.36 billion in 2020 and is expected to reach $ 99.65 billion by 2028, with a CAGR of 4.1% from 2021 to 2028.

The Global Cord Blood Stem Cell Market was valued at $ 1,535 million in 2020 and is expected to reach $ 4,756 million by 2028, growing at a CAGR of 5.3% from 2021 to 2028.

The Global Adult Stem Cell Market was valued at $ 6.94 billion in 2020 and is expected to reach $ 9.45 billion by 2028, growing at a CAGR of 7.5% from 2021 to 2028.

About Us:

At Vantage Market Research, we provide high quality, quantified B2B research on over 20,000
emerging markets, in turn, helping our clients map a constellation of opportunities for their businesses. We, as a market research and competitive intelligence consulting company, provide end-to-end solutions to our corporate clients to achieve their critical business goals. Our customer base spans 70% of Global Fortune 500 companies. The company provides high quality data and market research services. The company serves various businesses and clients in a wide variety of industries. The company offers detailed reports on several industries, including chemical materials and energy, food and beverage, health technology, and more. The company’s experienced team of analysts, researchers and consultants use proprietary data sources and numerous statistical tools and techniques to collect and analyze information.

Contact us

Eric Kunz

6218 Georgia Avenue NW Ste 1 – 564

Washington DC 20011-5125

United States Tel. : +1 202 380 9727

Email: sales@vantagemarketresearch.com

Latest press releases from Vantage Market Research @ https://www.vantagemarketresearch.com/insight/press-releases

Latest Vantage Market Research Blog @ https://www.vantagemarketresearch.com/insight/blogs

Previous Business News | Stock market and stock market news | Financial news
Next Police tie up car used in Young Dolph's murder to second shooting | WGN 720 radio